Group 1: Sales and Market Expansion - The company is currently experiencing normal production and operational conditions, with key financial data to be disclosed in the 2025 semi-annual report [2] - The company aims to selectively participate in domestic and international blood purification exhibitions and academic conferences based on market development plans [2] - The ASEAN market is identified as a key overseas target market, with sales already achieved in most ASEAN countries, particularly in Indonesia, Malaysia, Thailand, and Vietnam [3] Group 2: International Market Development - The company is accelerating the certification process for its blood purification products in Russia and Turkey, following successful registrations in countries like Indonesia, Peru, and Mexico [3] - The company has established a global self-certification system to enhance its international market layout and competitiveness [3] Group 3: Financial Performance and Shareholder Relations - The company has maintained a high dividend payout ratio and is focused on improving investor relations and information disclosure quality [3] - Future plans for share buybacks or increases in shareholding will be disclosed in accordance with legal regulations [3] Group 4: Product Development and Innovation - The company has not yet ventured into AI medical technology but is monitoring developments in this area for potential future applications [3] - The company is committed to innovation in blood purification products and exploring other treatment models to meet healthcare demands [5] Group 5: Manufacturing and Strategic Expansion - The company has established multiple manufacturing bases across China, enhancing its industry position and core competitiveness [4] - Future expansion into first-tier cities will be considered based on strategic needs [4]